| Literature DB >> 34185406 |
Zeina R Al Sayed1, Mariam Jouni1, Jean-Baptiste Gourraud1,2, Nadjet Belbachir1, Julien Barc1, Aurore Girardeau1, Virginie Forest1, Aude Derevier3, Anne Gaignerie3, Caroline Chariau3, Bastien Cimarosti1, Robin Canac1, Pierre Olchesqui1, Eric Charpentier1, Jean-Jacques Schott1,2, Richard Redon1,2, Isabelle Baró1, Vincent Probst1,2, Flavien Charpentier1,2, Gildas Loussouarn1, Kazem Zibara4, Guillaume Lamirault1,2, Patricia Lemarchand1,2, Nathalie Gaborit1.
Abstract
Entities:
Mesh:
Substances:
Year: 2021 PMID: 34185406 PMCID: PMC8181201 DOI: 10.1002/ctm2.413
Source DB: PubMed Journal: Clin Transl Med ISSN: 2001-1326
FIGURE 1Pluripotency and SCN5A variant validation in hiPSCs, and characterization of derived cardiomyocytes. (A) Transcript expression of pluripotency markers: NANOG and OCT3/4 in newly described hiPSCs as compared to fibroblasts (Fibro). (B) Representative immunostainings of TRA1‐60 (red) and OCT4 (green) in hiPSCs. (C) Percentage of hiPSCs expressing SSEA4 and TRA1‐60 evaluated by flow cytometry. (D) Genomic sequence chromatograms validating (right) the 5164A>G SCN5A variant carried by BrS1+ and (left) the SCN5A 1983‐1993 duplication carried by BrS2+ and non‐BrS, in the corresponding hiPSCs. (E) Principal component analysis (PCA) of 39 hiPSC samples and their corresponding differentiated hiPSC‐CMs, based on their expression pattern of 27106 analyzed transcripts (3′SRP data). All clones of each hiPSC line are highlighted. (F) Correlation matrix of hiPSCs and hiPSC‐CMs expression profiles. Yellow and orange indicate high and low correlation, respectively. Samples were clustered using an ascending hierarchical method with Pearson as metric and ward D2 linkage. (G) Heatmap showing expression levels of 9661 differentially expressed genes between hiPSCs and hiPSC‐CMs (same samples as in A). Genes were clustered using a hierarchical ascending method with an uncentered correlation metric and complete linkage. Yellow and blue indicate high and low levels, respectively. (H) Illustrative immunostainings of Troponin I (green) in hiPSC‐CMs. Nuclei were stained with DAPI (blue). (I) Percentages of nodal‐like, atrial‐like, and ventricular‐like cells classified based on the analysis of spontaneous action potential recordings
FIGURE 2Differential gene expression profiles and variations in I Na and I Ca,L, in BrS hiPSC‐CMs as compared to controls. (A) Heatmap showing hierarchical clustering of expression profiles of 133 differentially expressed genes obtained by 3′SRP in control (Ctrl) and BrS hiPSC‐CMs at day 28 of differentiation. A total of 27% were upregulated, whereas 73% genes were downregulated in BrS hiPSC‐CMs. Yellow and blue represent high and low expression levels, respectively. All clones of each hiPSC line are highlighted. (B) Gene set enrichment analysis (GSEA) of gene variations obtained by 3′SRP shows gene sets with statistically altered expression patterns. (C) MindMap describing the transmembrane transporter activity alterations. (D) Expression levels of differentially expressed genes identified using high‐throughput TaqMan (TLDA) in BrS hiPSC‐CMs (n = 14), compared to control hiPSC‐CMs (n = 12), and in non‐BrS hiPSC‐CMs (n = 4) versus BrS hiPSC‐CMs. p‐values: *, **, and *** or a, b, and c: p < .05, p < .01, and p < .001 versus Ctrl or BrS, respectively (t‐test). (E) Representative immunoblots for Nav1.5 and transferrin receptor (TFRC) in hiPSC‐CMs (left panel). Ratios of Nav1.5 expression levels (right panel, Tukey plot, n = 8). *p < .05 versus control (Mann–Whitney test). Nav1.5 decreases in hiPSC‐CMs from three subjects, BrS2+ and non‐BrS (both carrying a stop codon in SCN5A), as well as BrS5−, harboring RRAD variant was observed. (F) Representative superimposed I Na densities (inset: voltage‐clamp protocol). Reduction was detected in BrS2+, BrS5−, and non‐BrS, as well as in BrS1+ hiPSC‐CMs carrying the N1722D‐SCN5A rare variant. (G) Peak I Na densities measured in control (Ctrl), BrS, and the non‐affected carrier of SCN5A mutation (non‐BrS) hiPSC‐CMs determined at −20 mV (Tukey plot). ***p < .001 versus control (Mann–Whitney test). (H) Mean peak I Na densities (pA/pF) versus membrane potential (V m) recorded in hiPSC‐CMs. ****, $$$$, ####, and ^^^^ p < .0001 versus control for BrS1+, BrS2+, BrS5−, and non‐BrS, respectively (two‐way ANOVA with Bonferroni post hoc test). (I) Representative immunoblots for Cav1.2, the main pore‐forming subunit of the cardiac L‐type calcium channel, and transferrin receptor (TFRC) in hiPSC‐CMs (left panel). Ratios of Cav1.2 expression levels (right panel, Tukey plot, n = 8). A decrease in Cav1.2 expression was solely observed in BrS5− hiPSC‐CMs, carrying an RRAD‐variant. *p < .05 versus control (Mann–Whitney test). (J) Representative superimposed I Ca,L densities (inset: voltage protocol). (K) Peak I Ca,L densities measured in control (Ctrl), BrS, and the nonaffected carrier of SCN5A mutation (non‐BrS) hiPSC‐∖CMs determined at 0 mV (Tukey plot). A decrease in I Ca,L was observed in BrS2+, BrS4− and, consistently with a previous description, in BrS5−.7 *p < .05 and **p < .01 versus control (Mann–Whitney test). (L) Mean peak I Ca,L densities (pA/pF) versus membrane potential (V m) recorded in hiPSC‐CMs. *, #, and $ p < .05, **, ##, and $$ p < .01, and ***, ###, and $$$ p < .001 versus control for BrS1+, BrS4−, and BrS5−, respectively (two‐way ANOVA with Bonferroni post hoc test)
FIGURE 3Increased early after depolarization (EAD) occurrence in all BrS ventricular‐like hiPSC‐CM lines, linked to an increase in late sodium current. (A) Representative AP recordings, showing EADs in BrS lines only. Representative ventricular‐like AP when paced at 700 ms cycle length and when artificial I K1 was injected (dynamic current clamp). APs are defined as ventricular‐like when (APD30 − APD40)/(APD70 − APD80) > 1.45. (B) Percentage of ventricular‐like hiPSC‐CMs presenting at least 1 EAD, irrespective of the current clamp conditions. *p < .05, **p < .01, and ***p < .001 versus control (Fisher's exact test). (C) Representative I Na,L recordings from hiPSC‐CMs, before (black) and after (grey) TTX application (inset: voltage protocol). (D) I Na,L (TTX‐sensitive current) densities at −10 mV. *p < .05 and ***p < .001 versus Ctrl (Mann–Whitney test), and ## p < .01 and ### p < .001 versus non‐BrS (Mann–Whitney test). (E) Percentage of cells presenting I Na,L density greater than the 97th percentile value of I Na,L in the Ctrl hiPSC‐CMs. **p < .01 and ***p < .001 versus control (Fisher's exact test). Indeed, an increase in I Na,L density was defined by values higher than 97th percentile of the Ctrl hiPSC‐CMs. (F) Representative example of I Na,L current recorded in BrS hiPSC‐CMs before (black) and after (red) application with GS‐458967 (300 nM), a specific I Na,L inhibitor (inset: voltage protocol). (G) Representative AP recordings from control and BrS hiPSC‐CMs obtained before and after GS‐458967 application. (H) Percentage of cells with EADs before and after GS‐458967 application. (I) Poincaré plots showing APD90 of each AP (n + 1) versus APD90 of its preceding one, before and after GS‐458967 application
FIGURE 4Applying depolarizing ion current alterations from BrS hiPSC‐CMs on an electrogram model to mimic BrS patient's ECG features. (A) Top: Right ventricle electrogram model simulates the global electrical activity of a transmural wedge comprising 60 subendocardial, 45 midmyocardial, and 60 subepicardial human ventricular cells. Bottom: Representative electrogram showing the Q‐like, R‐like, S‐like and T‐like waves. (B) Ventricular transmural electrogram mathematical model of Ctrl (black), BrS2+ (pink), and non‐BrS (blue) illustrated based on hiPSC‐CMs data of the relative variation in ion currents (I Na, I Ca,L, and I Na,L) mean amplitude as compared to Ctrl lines. In accordance with patient's ECGs, applying BrS2+ ionic current changes prolonged the QRS‐like complex, elevated and widened the ST‐like segment, and inversed the T‐like wave; and applying I Na change identified in non‐BrS hiPSC‐CMs only prolonged the QRS‐like complex, similar to non‐BrS PCCD ECG. (C) Each of the currents I Na, I Ca,L, and I Na,L (from left to right) were sequentially corrected and the resulting electrograms are illustrated in green. Ctrl and BrS2+ electrograms are presented in black and pink, respectively